Ye Chenyang, Qi Lina, Wang Ji, Zheng Shu
Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), School of Medicine, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China.
Front Med (Lausanne). 2021 Mar 29;8:606755. doi: 10.3389/fmed.2021.606755. eCollection 2021.
Coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally and rapidly developed into a worldwide pandemic. The sudden outburst and rapid dissemination of SARS-CoV-2, with overwhelming public health and economic burdens, highlight an urgent need to develop effective strategies for the diagnosis and treatment of infected patients. In this review, we focus on the current advances in the diagnostics and treatment for SARS-CoV-2 infection. Notably, we also summarize some antineoplastic drugs repurposed for COVID-19 treatment and address the diagnostic and therapeutic challenges for oncologists to manage cancer patients in this COVID-19 era. In addition, we emphasize the importance of organoid technology as a valuable experimental virology platform to better understand the pathogenesis of COVID-19 and assist rapid screening of drugs against COVID-19.
由新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）已在全球范围内传播，并迅速发展成为一场全球大流行。SARS-CoV-2的突然爆发和迅速传播，带来了巨大的公共卫生和经济负担，凸显了迫切需要制定有效的策略来诊断和治疗感染患者。在本综述中，我们重点关注SARS-CoV-2感染诊断和治疗的当前进展。值得注意的是，我们还总结了一些重新用于COVID-19治疗的抗肿瘤药物，并探讨了在这个COVID-19时代肿瘤学家管理癌症患者所面临的诊断和治疗挑战。此外，我们强调类器官技术作为一个有价值的实验病毒学平台的重要性，以更好地了解COVID-19的发病机制，并协助快速筛选抗COVID-19药物。
